Autolus Limited

Mathieu Ferrari

Shimobi Onuoha

Martin Pulé

Shaun Cordoba

Simon Thomas

Biao Ma

Wen Chean Lim

Evangelia Kokalaki

Paul Maciocia

Alexander Kinna

Marco Della Peruta

Vania Baldan

Anna Bulek

Ana Margarida Neves

Antigen-Binding Domain

The present invention provides a chimeric antigen receptor (CAR) which binds a low density target antigen, which comprises a Fab antigen binding domain. The invention also relates to cells expressing such a CAR and their use in the treatment of disease.

Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptors

The present invention provides a variant antigen-binding domain which comprises at least one mutation in the VH domain compared to a reference antibody and which displays an increased affinity for TRBC2 over the reference antibody. It further provides an antibody, a chimeric antigen receptor (CAR), and a bispecific T-cell engager (BiTE), a cell which comprises said CAR, and a conjugate comprising said variant antigen-binding domain or said antibody. Additionally, it provides medical uses, diagnostic methods and methods of personalised medicine that exploit the products of the invention.

Binding domain

The present invention provides a chimeric antigen receptor (CAR) which specifically binds CD79 as well as a nucleic acid sequence and a vector encoding the CAR. It further provides a cell which expresses the CAR at the cell surface.

CD79-specific chimeric antigen receptor

Chimeric antigen receptor

The present invention provides a chimeric antigen receptor (CAR) which binds a target antigen having a bulky extracellular domain, wherein the CAR comprises a Fab antigen binding domain. The present invention also provides nucleic acid sequences and constructs encoding such a CAR, cells expressing such a CAR and their therapeutic uses.

The present invention provides antibodies and polyclonal antibody preparations which bind the intracellular portion of either T-cell receptor constant region 2 (TRBC2) or T-cell receptor constant region 1 (TRBC1). The antibodies can be used to determine whether a T-cell malignancy clonally expresses TRBC1 or TRBC2.

T-cell receptor constant region 1 antibody or T-cell receptor constant region 2 antibody

Growing community of inventors

London, United Kingdom

Mathieu Ferrari